TTIPF (Thiogenesis Therapeutics) Effective Interest Rate on Debt %: 0.00% (As of Mar. 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Effective Interest Rate on Debt %?

Thiogenesis Therapeutics TTIPF -6.67% 12 Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Thiogenesis Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.00 Mil. Thiogenesis Therapeutics's average total debt for the quarter that ended in Mar. 2026 was $0.00 Mil. Therefore, Thiogenesis Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was N/A%.


Thiogenesis Therapeutics  (OTCPK:TTIPF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Thiogenesis Therapeutics Effective Interest Rate on Debt % Related Terms


Thiogenesis Therapeutics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics Effective Interest Rate on Debt % Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TTIPF vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Thiogenesis Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thiogenesis Therapeutics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Effective Interest Rate on Debt % falls into.


TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics Effective Interest Rate on Debt % Calculation

Thiogenesis Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  0/( (0+0)/ 1 )
=-1  *  0/0
=N/A %

where

Thiogenesis Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2025 )+Total Debt  (Q: Mar. 2026 ))/ count )
=-1  *  0/( (0+0)/ 1 )
=-1  *  0/0
=N/A %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 0.00% mean?
Thiogenesis Therapeutics (TTIPF) has a Effective Interest Rate on Debt % of 0.00% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Thiogenesis Therapeutics and its competitors.
Is Thiogenesis Therapeutics' Effective Interest Rate on Debt % too high?
Thiogenesis Therapeutics' current Effective Interest Rate on Debt % is 0.00%. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Effective Interest Rate on Debt % compare to VRTX and REGN?
Thiogenesis Therapeutics' Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price